Douglas Grossman
( out of 293 reviews )

Douglas Grossman, MD, PhD

Languages spoken: English

Clinical Locations

Huntsman Cancer Institute - Cancer Hospital South

Clinic 2C, Dermatology/Melanoma
Salt Lake City
801-581-2955

  • Douglas Grossman, MD, PhD, is an investigator in Huntsman Cancer Institute's (HCI) Melanoma Program and a Professor in the Department of Dermatology at the University of Utah School of Medicine. He is Co-Leader of the Melanoma center at HCI. He sees patients at risk for melanoma and non-melanoma skin cancer, with a special interest in patients who have a personal or family history of melanoma; numerous and/or atypical moles (nevi); a personal history of basal or squamous cell carcinoma; or a history of excessive sun exposure. Grossman had directed the Mole Mapping Program at HCI since 2004.

    Grossman's lab studies mechanisms of tumor development and metastasis in melanoma. In addition, they study the role of UV-induced oxidative stress and DNA damage using human nevi (moles) as a model system. They are using this knowledge to develop novel chemopreventive agents for patients at increased risk for melanoma.

    Grossman received his MD and PhD from Baylor College of Medicine, completed an internship at Yale-New Haven Hospital, and completed a dermatology residency at Yale. He remained at Yale for a research fellowship in cancer biology, and then joined Huntsman Cancer Institute and the University of Utah School of Medicine faculty in 2001.

    Douglas Grossman, MD, PhD, is an expert in the early diagnosis and treatment of skin cancers. He received his medical degree from Baylor College of Medicine in 1994, and completed his dermatology training at Yale University School of Medicine in 1998. Following a research fellowship in cancer biology at Yale, he was recruited to the University of Utah in 2001. He sees patients with a personal history of skin cancer or excessive sun exposure, and those at increased risk for melanoma who may have numerous or atypical moles or family members with melanoma. He directs the Mole Mapping Program at the Huntsman Cancer Institute.

    Specialties

    Board Certification

    American Board of Dermatology (Dermatology)

    Patient Rating

    4.9 /5
    ( out of 293 reviews )

    The patient rating score is an average of all responses on our patient experience survey. The rating averages scores for all questions about care from our providers.

    The scale on which responses are measured is 1 to 5 with 5 being the best score.

    Patient Comments

    Patient comments are gathered from our patient experience survey and displayed in their entirety.
    Patients are de-identified for confidentiality and patient privacy.

    October 30, 2024
    HUNTSMAN CANCER CENTER

    Dr. Grossman cares about his patients and is careful to make certain your questions and concerns are addressed in a manner you understand. am very happy to have him as my Dr.

    October 29, 2024
    HUNTSMAN CANCER CENTER

    Dr. Grossman is alert, helpful, and efficient.

    October 29, 2024
    HUNTSMAN CANCER CENTER

    Thank you for taking such good care of me and explaining everything.

    October 29, 2024
    HUNTSMAN CANCER CENTER

    One of the best doctors I've ever had.

    October 29, 2024
    HUNTSMAN CANCER CENTER

    Dr. Doug Grossman is a perfect doctor and very professional; the staff was alert and ready and the operation and procedure went smoothly.

    October 21, 2024
    HUNTSMAN CANCER CENTER

    Very kind and thorough. I appreciate his expertise .

    October 20, 2024
    HUNTSMAN CANCER CENTER

    Very caring and l felt he really listened to me and is going to take care of my problem.

    October 20, 2024
    HUNTSMAN CANCER CENTER

    My choice after moving here from Florida 12 yrs ago.

    October 19, 2024
    HUNTSMAN CANCER CENTER

    Always a good appointment with Dr. Grossman.

    See More Patient Comments

  • Douglas Grossman, MD, PhD, is an investigator in Huntsman Cancer Institute's (HCI) Melanoma Program and a Professor in the Department of Dermatology at the University of Utah School of Medicine. He is Co-Leader of the Melanoma center at HCI. He sees patients at risk for melanoma and non-melanoma skin cancer, with a special interest in patients who have a personal or family history of melanoma; numerous and/or atypical moles (nevi); a personal history of basal or squamous cell carcinoma; or a history of excessive sun exposure. Grossman had directed the Mole Mapping Program at HCI since 2004.

    Grossman's lab studies mechanisms of tumor development and metastasis in melanoma. In addition, they study the role of UV-induced oxidative stress and DNA damage using human nevi (moles) as a model system. They are using this knowledge to develop novel chemopreventive agents for patients at increased risk for melanoma.

    Grossman received his MD and PhD from Baylor College of Medicine, completed an internship at Yale-New Haven Hospital, and completed a dermatology residency at Yale. He remained at Yale for a research fellowship in cancer biology, and then joined Huntsman Cancer Institute and the University of Utah School of Medicine faculty in 2001.

    Douglas Grossman, MD, PhD, is an expert in the early diagnosis and treatment of skin cancers. He received his medical degree from Baylor College of Medicine in 1994, and completed his dermatology training at Yale University School of Medicine in 1998. Following a research fellowship in cancer biology at Yale, he was recruited to the University of Utah in 2001. He sees patients with a personal history of skin cancer or excessive sun exposure, and those at increased risk for melanoma who may have numerous or atypical moles or family members with melanoma. He directs the Mole Mapping Program at the Huntsman Cancer Institute.

    Board Certification and Academic Information

    Academic Departments Dermatology -Primary
    Board Certification
    American Board of Dermatology (Dermatology)

    Education history

    Fellowship Laboratory of Dario C. Altieri, M.D. - Yale University School of Medicine Fellow
    Dermatology - Yale University School of Medicine Resident
    Internship Internal Medicine - Yale New Haven Hospital Intern
    Immunology; Laboratory of Robert R. Rich, M.D - Baylor College of Medicine Ph.D.
    Professional Medical Medicine - Baylor College of Medicine M.D.
    Chemistry - Duke University B.S.

    Selected Publications

    Journal Article

    1. Wu YP, Stump TK, Hay JL, Aspinwall LG, Boucher KM, Deboeck PR, Grossman D, Mooney K, Leachman SA, Smith KR, Wankier AP, Brady HL, Hancock SE, Parsons BG, Tercyak KP (2023). The Family Lifestyles, Actions and Risk Education (FLARE) study: Protocol for a randomized controlled trial of a sun protection intervention for children of melanoma survivors. Contemp Clin Trials, 131, 107276. (Read full article)
    2. Rahman H, Liu T, Askaryar S, Grossman D (2022). Aspirin Protects against UVB-Induced DNA Damage through Activation of AMP Kinase. J Invest Dermatol, 143(1), 154-162.e3. (Read full article)
    3. Elkeeb DM, Hopkins ZH, Bolender CM, Moreno C, Florell SR, Bowen AR, Vitale P, Zussman J, Duffy K, Grossman D, Secrest AM, Wada DA (2022). A Single-Institution Cohort Study With Nevi of Special Site: Recurrence, Progression to Melanoma, and Patterns of Management. Am J Dermatopathol, 45(1), 28-39. (Read full article)
    4. Brady HL, Hamilton JG, Kaphingst KA, Jensen JD, Kohlmann W, Parsons BG, Lillie HM, Wankier AP, Smith HJ, Grossman D, Hay JL, Wu YP (2022). 'I had a bigger cancer risk than I thought…': The experience of receiving personalized risk information as part of a skin cancer prevention intervention in the college setting. Health Expect, 25(6), 2937-2949. (Read full article)
    5. Trepanowski N, Chang MS, Zhou G, Ahmad M, Berry EG, Bui K, Butler WH, Chu EY, Curiel-Lewandrowski C, Dellalana LE, Ellis DL, Freeman SC, Gorrepati PL, Grossman D, Gyurdzhyan S, Kanetsky PA, King ALO, Kolla AM, Lian CG, Lin JY, Liu V, Lowenthal A, McCoy KN, Munjal A, Myrdal CN, Perkins S, Powers JG, Rauck C, Smart TC, Stein JA, Venna S, Walsh ME, Wang JY, Leachman SA, Swetter SM, Hartman RI (2022). Delays in melanoma presentation during the COVID-19 pandemic: A nationwide multi-institutional cohort study. J Am Acad Dermatol, 87(5), 1217-1219. (Read full article)
    6. Wu YP, Hamilton JG, Kaphingst KA, Jensen JD, Kohlmann W, Parsons BG, Lillie HM, Wang X, Haaland B, Wankier AP, Grossman D, Hay JL (2022). Increasing Skin Cancer Prevention in Young Adults: the Cumulative Impact of Personalized UV Photography and MC1R Genetic Testing. J Cancer Educ, 38(3), 1059-1065. (Read full article)
    7. Wu YP, Parsons B, Jo Y, Chipman J, Haaland B, Nagelhout ES, Carrington J, Wankier AP, Brady H, Grossman D (2022). Outdoor activities and sunburn among urban and rural families in a Western region of the US: Implications for skin cancer prevention. Prev Med Rep, 29, 101914. (Read full article)
    8. Himbert C, Hathaway CA, Daniels B, Salas K, Ashworth A, Gigic B, Lin T, Viskochil R, Kirchhoff AC, Grossman D, Ose J, Tward J, Scaife C, Figueiredo JC, Toriola AT, Beck A, Shibata D, Gonzalez BD, Matsen C, Christenson C, Ma DS, Colman H, Hunt JP, Jones KB, Lee CJ, Larson M, Onega T, Akerley WL, Li CI, Schneider M, Penedo FJ, Siegel EM, Tworoger SS, Ulrich CM, Peoples AR (2022). Factors associated with changes in exercise behaviors during the COVID-19 pandemic. Cancer Causes Control, 33(7), 939-950. (Read full article)
    9. Peoples AR, Oswald LB, Ose J, Daniels B, Himbert C, Hathaway CA, Gigic B, Kirchhoff AC, Lin T, Grossman D, Tward J, Varghese TK Jr, Figueiredo JC, Toriola AT, Beck A, Scaife C, Shibata D, LaStayo P, Gonzalez B, Salas K, Ashworth A, Matsen C, Christenson C, Ma DS, Colman H, Hunt JP, Jones KB, Lee CJ, Larson M, Onega T, Akerley WL, Li CI, Schneider M, Penedo FJ, Siegel EM, Tworoger SS, Ulrich CM (2022). Impact of the COVID-19 pandemic on rural and urban cancer patients' experiences, health behaviors, and perceptions. J Rural Health, 38(4), 886-899. (Read full article)
    10. Luo X, Zhou Y, Smart T, Grossman D, Sanchez B (2021). Electrical Characterization of Basal Cell Carcinoma Using a Handheld Electrical Impedance Dermography Device. JID Innov, 2(1), 100075. (Read full article)
    11. McNeal AS, Belote RL, Zeng H, Urquijo M, Barker K, Torres R, Curtin M, Shain AH, Andtbacka RH, Holmen S, Lum DH, McCalmont TH, VanBrocklin MW, Grossman D, Wei ML, Lang UE, Judson-Torres RL (2021). BRAFV600E induces reversible mitotic arrest in human melanocytes via microrna-mediated suppression of AURKB. Elife, 10. (Read full article)
    12. Okwundu N, Rahman H, Liu T, Florell SR, Boucher KM, Grossman D (2021). A randomized double-blind placebo-controlled trial of oral aspirin for protection of melanocytic nevi against UV-induced DNA damage. Cancer Prev Res (Phila), 15, 129-138. (Read full article)
    13. Parsons BG, Nagelhout ES, Wankier AP, Hu N, Lensink R, Zhu A, Nottingham K, Grossman D, Jensen JD, Wu YP (2021). Reactivity to UV Radiation Exposure Monitoring Using Personal Exposure Devices for Skin Cancer Prevention: Longitudinal Observational Study. JMIR Mhealth Uhealth, 9(9), e29694. (Read full article)
    14. Okwundu N, Grossman D, Hu-Lieskovan S, Grossmann KF, Swami U (2020). The dark side of immunotherapy. Ann Transl Med, 9(12), 1041. (Read full article)
    15. Haynes D, Strunck JL, Said J, Tam I, Varedi A, Topham CA, Olamiju B, Wei BM, Erickson MK, Wang LL, Tan A, Stoner R, Hartman RI, Lilly E, Grossman D, Curtis JA, Westerdahl JS, Leventhal JS, Choi JN, Chu EY, Ming ME, Stein JA, Liebman TN, Berry E, Greiling TM (2020). Association between halo nevi and melanoma in adults: A multicenter retrospective case series. J Am Acad Dermatol, 84(4), 1164-1166. (Read full article)
    16. Nagelhout ES, Lensink R, Zhu A, Parsons BG, Haaland B, Hashibe M, Grossman D, VanDerslice J, Gren LH, Jensen JD, Wu YP (2022). Higher Ultraviolet Radiation Exposure Among Rural-Dwelling Versus Urban-Dwelling Adults and Children: Implications for Skin Cancer Prevention. J Community Health, 46(1), 147-155. (Read full article)
    17. Flint ND, Bishop MD, Smart TC, Strunck JL, Boucher KM, Grossman D, Secrest AM (2020). Low accuracy of self-reported family history of melanoma in high-risk patients. Fam Cancer, 20(1), 41-48. (Read full article)
    18. Rahman H, Kumar D, Liu T, Okwundu N, Lum D, Florell SR, Burd CE, Boucher KM, VanBrocklin MW, Grossman D (2020). Aspirin Protects Melanocytes and Keratinocytes against UVB-Induced DNA Damage In Vivo. J Invest Dermatol, 141(1), 132-141.e3. (Read full article)
    19. Hawryluk EB, Moustafa D, Bartenstein D, Brahmbhatt M, Cordoro K, Gardner L, Gauthier A, Grossman D, Gupta D, Hunt RD, Jen M, Kao PC, Kruse LL, Lawley LP, London WB, Mansour D, OHaver JA, Phung T, Pope E, Price HN, Rogers T, Shah SD, Wolner Z, Huang J, Marghoob AA (2020). A retrospective multicenter study of fatal pediatric melanoma. J Am Acad Dermatol, 83(5), 1274-1281. (Read full article)
    20. Grossman D, Okwundu N, Bartlett EK, Marchetti MA, Othus M, Coit DG, Hartman RI, Leachman SA, Berry EG, Korde L, Lee SJ, Bar-Eli M, Berwick M, Bowles T, Buchbinder EI, Burton EM, Chu EY, Curiel-Lewandrowski C, Curtis JA, Daud A, Deacon DC, Ferris LK, Gershenwald JE, Grossmann KF, Hu-Lieskovan S, Hyngstrom J, Jeter JM, Judson-Torres RL, Kendra KL, Kim CC, Kirkwood JM, Lawson DH, Leming PD, Long GV, Marghoob AA, Mehnert JM, Ming ME, Nelson KC, Polsky D, Scolyer RA, Smith EA, Sondak VK, Stark MS, Stein JA, Thompson JA, Thompson JF, Venna SS, Wei ML, Swetter SM (2020). Prognostic Gene Expression Profiling in Cutaneous Melanoma: Identifying the Knowledge Gaps and Assessing the Clinical Benefit. JAMA Dermatol, 156(9), 1004-1011. (Read full article)
    21. Parsons BG, Hay JL, Aspinwall LG, Zaugg K, Zhu A, Mooney RH, Klein SZ, Grossman D, Leachman SA, Wu YP (2019). Understanding Skin Screening Practices Among Children at Elevated Risk for Melanoma to Inform Interventions for Melanoma Prevention and Control. J Cancer Educ, 35(3), 509-514. (Read full article)
    22. Li C, Liu T, Tavtigian SV, Boucher K, Kohlmann W, Cannon-Albright L, Grossman D (2019). Targeted germline sequencing of patients with three or more primary melanomas reveals high rate of pathogenic variants. Melanoma Res, 30(3), 247-251. (Read full article)
    23. Hyde MA, Grossman D, Wu YP, Buys S, Gren LH, Hashibe M (2020). Vitamin D, melanoma risk, and tumor thickness in PLCO cancer screening trial patients. JAAPA, 33(6), 35-41. (Read full article)
    24. Truong A, Hyngstrom JR, Andtbacka RHI, Noyes RD, Wright M, Snyder J, Winters A, Sause WT, Grossmann KF, Khong HT, Bowen GM, Hitchcock YJ, Grossman D, Bowles TL (2019). Recurrence risk of early-stage melanoma of the external ear: an investigation of surgical approach and sentinel lymph node status. Melanoma Res, 30(2), 173-178. (Read full article)
    25. Jensen JD, Pokharel M, King AJ, John KK, Wu YP, Grossman D (2019). Obstacles to skin self-examination: are frontier adults inclined abstainers? Psychol Health Med, 25(4), 470-479. (Read full article)
    26. Strunck JL, Smart TC, Boucher KM, Secrest AM, Grossman D (2020). Improved melanoma outcomes and survival in patients monitored by total body photography: A natural experiment. J Dermatol, 47(4), 342-347. (Read full article)
    27. Varedi A, Rahman H, Kumar D, Catrow JL, Cox JE, Liu T, Florell SR, Boucher KM, Okwundu N, Burnett WJ, VanBrocklin MW, Grossman D (2020). ASA Suppresses PGE2 in Plasma and Melanocytic Nevi of Human Subjects at Increased Risk for Melanoma. Pharmaceuticals (Basel), 13(1). (Read full article)
    28. Wu YP, Boucher K, Hu N, Hay J, Kohlmann W, Aspinwall LG, Bowen DJ, Parsons BG, Nagelhout ES, Grossman D, Mooney K, Leachman SA, Tercyak KP (2019). A pilot study of a telehealth family-focused melanoma preventive intervention for children with a family history of melanoma. Psychooncology, 29(1), 148-155. (Read full article)
    29. Grossman D, Kim CC, Hartman RI, Berry E, Nelson KC, Okwundu N, Curiel-Lewandrowski C, Leachman SA, Swetter SM (2019). Prognostic gene expression profiling in melanoma: necessary steps to incorporate into clinical practice. Melanoma Manag, 6(4), MMT32. (Read full article)
    30. Nagelhout ES, Parsons BG, Haaland B, Tercyak KP, Zaugg K, Zhu A, Harding G, Yancey J, Jensen JD, Grossman D, Wetter DW, Wu YP (2019). Differences in reported sun protection practices, skin cancer knowledge, and perceived risk for skin cancer between rural and urban high school students. Cancer Causes Control, 30(11), 1251-1258. (Read full article)
    31. Marsh RA, Leiding JW, Logan BR, Griffith LM, Arnold DE, Haddad E, Falcone EL, Yin Z, Patel K, Arbuckle E, Bleesing JJ, Sullivan KE, Heimall J, Burroughs LM, Skoda-Smith S, Chandrakasan S, Yu LC, Oshrine BR, Cuvelier GDE, Thakar MS, Chen K, Teira P, Shenoy S, Phelan R, Forbes LR, Chellapandian D, Dvila Saldaa BJ, Shah AJ, Weinacht KG, Joshi A, Boulad F, Quigg TC, Dvorak CC, Grossman D, Torgerson T, Graham P, Prasad V, Knutsen A, Chong H, Miller H, de la Morena MT, DeSantes K, Cowan MJ, Notarangelo LD, Kohn DB, Stenger E, Pai SY, Routes JM, Puck JM, Kapoor N, Pulsipher MA, Malech HL, Parikh S, Kang EM, submitted on behalf of the Primary Immune Deficiency Treatment Consortium (2019). Chronic Granulomatous Disease-Associated IBD Resolves and Does Not Adversely Impact Survival Following Allogeneic HCT. J Clin Immunol, 39(7), 653-667. (Read full article)
    32. Li C, Liu T, Liu B, Hernandez R, Facelli JC, Grossman D (2019). A novel CDKN2A variant (p16L117P ) in a patient with familial and multiple primary melanomas. Pigment Cell Melanoma Res, 32(5), 734-738. (Read full article)
    33. Wu YP, Parsons BG, Aspinwall LG, Hay JL, Boucher KM, Caputo H, Mooney R, Grossman D, Leachman SA (2019). Parent and child perspectives on perceived barriers to child sun protection and their association with sun protection strategies among children of melanoma survivors. Pediatr Dermatol, 36(3), 317-323. (Read full article)
    34. Gardner LJ, Strunck JL, Wu YP, Grossman D (2018). Current controversies in early-stage melanoma: Questions on incidence, screening, and histologic regression. J Am Acad Dermatol, 80(1), 1-12. (Read full article)
    35. Klapperich ME, Bowen GM, Grossman D (2018). Current controversies in early-stage melanoma: Questions on management and surveillance. J Am Acad Dermatol, 80(1), 15-25. (Read full article)
    36. Jeter JM, Bowles TL, Curiel-Lewandrowski C, Swetter SM, Filipp FV, Abdel-Malek ZA, Geskin LJ, Brewer JD, Arbiser JL, Gershenwald JE, Chu EY, Kirkwood JM, Box NF, Funchain P, Fisher DE, Kendra KL, Marghoob AA, Chen SC, Ming ME, Albertini MR, Vetto JT, Margolin KA, Pagoto SL, Hay JL, Grossman D, Ellis DL, Kashani-Sabet M, Mangold AR, Markovic SN, Meyskens FL Jr, Nelson KC, Powers JG, Robinson JK, Sahni D, Sekulic A, Sondak VK, Wei ML, Zager JS, Dellavalle RP, Thompson JA, Weinstock MA, Leachman SA, Cassidy PB (2018). Chemoprevention agents for melanoma: A path forward into phase 3 clinical trials. Cancer, 125(1), 18-44. (Read full article)
    37. Kim CC, Berry EG, Marchetti MA, Swetter SM, Lim G, Grossman D, Curiel-Lewandrowski C, Chu EY, Ming ME, Zhu K, Brahmbhatt M, Balakrishnan V, Davis MJ, Wolner Z, Fleming N, Ferris LK, Nguyen J, Trofymenko O, Liu Y, Chen SC, Pigmented Lesion Subcommittee, Melanoma Prevention Working Group (2018). Risk of Subsequent Cutaneous Melanoma in Moderately Dysplastic Nevi Excisionally Biopsied but With Positive Histologic Margins. JAMA Dermatol, 154(12), 1401-1408. (Read full article)
    38. Teerlink CC, Huff C, Stevens J, Yu Y, Holmen SL, Silvis MR, Trombetti K, Zhao H, Grossman D, Farnham JM, Wen J, Facelli JC, Thomas A, Babst M, Florell SR, Meyer L, Zone JJ, Leachman S, Cannon-Albright LA (2018). A Nonsynonymous Variant in the GOLM1 Gene in Cutaneous Malignant Melanoma. J Natl Cancer Inst, 110(12), 1380-1385. (Read full article)
    39. Kumar D, Rahman H, Tyagi E, Liu T, Li C, Lu R, Lum D, Holmen SL, Maschek JA, Cox JE, VanBrocklin MW, Grossman D (2018). Aspirin Suppresses PGE2 and Activates AMP Kinase to Inhibit Melanoma Cell Motility, Pigmentation, and Selective Tumor Growth In Vivo. Cancer Prev Res (Phila), 11(10), 629-642. (Read full article)
    40. Wu YP, Parsons BG, Mooney R, Aspinwall LG, Cloyes K, Hay JL, Kohlmann W, Grossman D, Leachman SA (2018). Barriers and Facilitators to Melanoma Prevention and Control Behaviors Among At-Risk Children. J Community Health, 43(5), 993-1001. (Read full article)
    41. Wu YP, Aspinwall LG, Nagelhout E, Kohlmann W, Kaphingst KA, Homburger S, Perkins RD, Grossman D, Harding G, Cassidy P, Leachman SA (2018). Development of an Educational Program Integrating Concepts of Genetic Risk and Preventive Strategies for Children with a Family History of Melanoma. J Cancer Educ, 33(4), 774-781. (Read full article)
    42. Grossman D, Farnham JM, Hyngstrom J, Klapperich ME, Secrest AM, Empey S, Bowen GM, Wada D, Andtbacka RHI, Grossmann K, Bowles TL, Cannon-Albright LA (2018). Similar survival of patients with multiple versus single primary melanomas based on Utah Surveillance, Epidemiology, and End Results data (1973-2011). J Am Acad Dermatol, 79(2), 238-244. (Read full article)
    43. Nelson KC, Grossman D, Kim CC, Chen SC, Curiel-Lewandrowski CN, Grichnik JM, Kirkwood JM, Leachman SA, Marghoob AA, Swetter SM, Venna SS, Ming ME (2018). Management strategies of academic pigmented lesion clinic directors in the United States. J Am Acad Dermatol, 79(2), 367-369. (Read full article)
    44. John KK, Jensen JD, King AJ, Pokharel M, Grossman D (2018). Emerging applications of eye-tracking technology in dermatology. J Dermatol Sci. (Read full article)
    45. Parsons BG, Gren LH, Simonsen SE, Harding G, Grossman D, Wu YP (2018). Opportunities for Skin Cancer Prevention Education among Individuals Attending a Community Skin Cancer Screening in a High-Risk Catchment Area. J Community Health, 43(2), 212-219. (Read full article)
    46. Grossman D, Bowen GM (2018). Commentary on Impact of National Comprehensive Cancer Network Guidelines on Case Selection and Outcomes for Sentinel Lymph Node Biopsy in Thin Melanoma. Dermatol Surg, 44(4), 502-503. (Read full article)
    47. Strunck JL, Florell SR, Grossman D (2018). Capillary hemangioma associated with dermal atrophy masquerading as a deep fungal infection.LID - 13030/qt4109m7ds [pii]. Dermatol Online J, 24(3). (Read full article)
    48. Wu YP, Nagelhout E, Aspinwall LG, Boucher KM, Parsons BG, Kohlmann W, Kaphingst KA, Homburger S, Perkins RD, Grossman D, Harding G, Leachman SA (2018). A novel educational intervention targeting melanoma risk and prevention knowledge among children with a familial risk for melanoma. Patient Educ Couns, 101(3), 452-459. (Read full article)
    49. Wu YP, Kohlmann W, Curtin K, Yu Z, Hanson HA, Hashibe M, Parsons BG, Wong J, Schiffman JD, Grossman D, Leachman SA (2018). Melanoma risk assessment based on relatives' age at diagnosis. Cancer Causes Control, 29(2), 193-199. (Read full article)
    50. Robinson JP, Rebecca VW, Kircher DA, Silvis MR, Smalley I, Gibney GT, Lastwika KJ, Chen G, Davies MA, Grossman D, Smalley KSM, Holmen SL, VanBrocklin MW (2017). Resistance mechanisms to genetic suppression of mutant NRAS in melanoma. Melanoma Res, 27(6), 545-557. (Read full article)
    51. Gardner LJ, Ward M, Andtbacka RHI, Boucher KM, Bowen GM, Bowles TL, Cohen AL, Grossmann K, Hitchcock YJ, Holmen SL, Hyngstrom J, Khong H, McMahon M, Monroe MM, Ross CB, Suneja G, Wada D, Grossman D (2017). Risk factors for development of melanoma brain metastasis and disease progression: a single-center retrospective analysis. Melanoma Res, 27(5), 477-484. (Read full article)
    52. John KK, Jensen JD, King AJ, Ratcliff CL, Grossman D (2017). Do Pattern-Focused Visuals Improve Skin Self-Examination Performance? Explicating the Visual Skill Acquisition Model. J Health Commun, 22(9), 732-742. (Read full article)
    53. Casey MJ, Modzelewska K, Anderson D, Goodman J, Boer EF, Jimenez L, Grossman D, Stewart RA (2017). A zebrafish brain tumor transplantation method for the long-term study of tumor cell behavior and drug response. J Vis Exp, 123, e55712.
    54. Tyagi E, Liu B, Li C, Liu T, Rutter J, Grossman D (2017). Loss of p16INK4A stimulates aberrant mitochondrial biogenesis through a CDK4/Rb-independent pathway. Oncotarget, 8(34), 55848-55862. (Read full article)
    55. Johnson MM, Leachman SA, Aspinwall LG, Cranmer LD, Curiel-Lewandrowski C, Sondak VK, Stemwedel CE, Swetter SM, Vetto J, Bowles T, Dellavalle RP, Geskin LJ, Grossman D, Grossmann KF, Hawkes JE, Jeter JM, Kim CC, Kirkwood JM, Mangold AR, Meyskens F, Ming ME, Nelson KC, Piepkorn M, Pollack BP, Robinson JK, Sober AJ, Trotter S, Venna SS, Agarwala S, Alani R, Averbook B, Bar A, Becevic M, Box N, E Carson W 3rd, Cassidy PB, Chen SC, Chu EY, Ellis DL, Ferris LK, Fisher DE, Kendra K, Lawson DH, Leming PD, Margolin KA, Markovic S, Martini MC, Miller D, Sahni D, Sharfman WH, Stein J, Stratigos AJ, Tarhini A, Taylor MH, Wisco OJ, Wong MK (2017). Skin cancer screening: recommendations for data-driven screening guidelines and a review of the US Preventive Services Task Force controversy. Melanoma Manag, 4(1), 13-37. (Read full article)
    56. Cassidy PB, Liu T, Florell SR, Honeggar M, Leachman SA, Boucher KM, Grossman D (2017). A Phase II Randomized Placebo-Controlled Trial of Oral N-acetylcysteine for Protection of Melanocytic Nevi against UV-Induced Oxidative Stress In Vivo. Cancer Prev Res (Phila), 10(1), 36-44. (Read full article)
    57. Ray A, Williams MA, Meek SM, Bowen RC, Grossmann KF, Andtbacka RHI, Bowles TL, Hyngstrom JR, Leachman SA, Grossman D, Bowen GM, Holmen SL, VanBrocklin MW, Suneja G, Khong HT (2016). Intratumoral ipilimumab and interleukin-2 produce high rates of abscopal responses with low toxicity in patients with advanced melanoma. JAMA Oncol, 7(39), 64390-99.
    58. Ray A, Williams MA, Meek SM, Bowen RC, Grossmann KF, Andtbacka RH, Bowles TL, Hyngstrom JR, Leachman SA, Grossman D, Bowen GM, Holmen SL, VanBrocklin MW, Suneja G, Khong HT (2016). A phase I study of intratumoral ipilimumab and interleukin-2 in patients with advanced melanoma. Oncotarget, 7(39), 64390-64399. (Read full article)
    59. Truong A, Strazzulla L, March J, Boucher KM, Nelson KC, Kim CC, Grossman D (2016). Reduction in nevus biopsies in patients monitored by total body photography. J Am Acad Dermatol, 75(1), 135-143.e5. (Read full article)
    60. March J, Hand M, Grossman D (2015). Practical application of new technologies for melanoma diagnosis: Part I. Noninvasive approaches. J Am Acad Dermatol, 72(6), 929-41; quiz 941-2. (Read full article)
    61. Goodson AG, Varedi A, Hull C, Grossman D (2015). A safe and efficient model for ultraviolet radiation-induced herpes simplex labialis. Photodermatol Photoimmunol Photomed, 31(3), 170-2. (Read full article)
    62. Soltani-Arabshahi R, Sweeney C, Jones B, Florell SR, Hu N, Grossman D (2015). Predictive value of biopsy specimens suspicious for melanoma: support for 6-mm criterion in the ABCD rule. J Am Acad Dermatol, 72(3), 412-8. (Read full article)
    63. King AJ, Carcioppolo N, Grossman D, John KK, Jensen JD (2015). A randomised test of printed educational materials about melanoma detection: Varying skin self-examination technique and visual image dose. Health Educ J, 74, 732-42.
    64. Malvehy J, Hauschild A, Curiel-Lewandrowski C, Mohr P, Hofmann-Wellenhof R, Motley R, Berking C, Grossman D, Paoli J, Loquai C, Olah J, Reinhold U, Wenger H, Dirschka T, Davis S, Henderson C, Rabinovitz H, Welzel J, Schadendorf D, Birgersson U (2014). Clinical performance of the Nevisense system in cutaneous melanoma detection: an international, multicentre, prospective and blinded clinical trial on efficacy and safety. Br J Dermatol, 171(5), 1099-107. (Read full article)
    65. Goodman JR, Grossman D (2014). Aspirin and other NSAIDs as chemoprevention agents in melanoma. Cancer Prev Res (Phila), 7(6), 557-64. (Read full article)
    66. King AJ, Gehl RW, Grossman D, Jensen JD (2013). Skin self-examinations and visual identification of atypical nevi: comparing individual and crowdsourcing approaches. Cancer Epidemiol, 37(6), 979-84. (Read full article)
    67. McKenzie JA, Liu T, Jung JY, Jones BB, Ekiz HA, Welm AL, Grossman D (2013). Survivin promotion of melanoma metastasis requires upregulation of α5 integrin. Carcinogenesis, 34(9), 2137-44. (Read full article)
    68. Jenkins NC, Jung J, Liu T, Wilde M, Holmen SL, Grossman D (2013). Familial melanoma-associated mutations in p16 uncouple its tumor-suppressor functions. J Invest Dermatol, 133(4), 1043-51. (Read full article)
    69. Grossman D, Bowen GM (2013). Commentary: transecting melanomas: does it matter? Dermatol Surg, 39(4), 616-7. (Read full article)
    70. Cassidy PB, Fain HD, Cassidy JP Jr, Tran SM, Moos PJ, Boucher KM, Gerads R, Florell SR, Grossman D, Leachman SA (2013). Selenium for the prevention of cutaneous melanoma. Nutrients, 5(3), 725-49. (Read full article)
    71. Andtbacka RH, Donaldson MR, Bowles TL, Bowen GM, Grossmann K, Khong H, Grossman D, Anker C, Florell SR, Bowen A, Duffy KL, Leachman SA, Noyes RD (2013). Sentinel lymph node biopsy for melanoma in pregnant women. Ann Surg Oncol, 20(2), 689-96. (Read full article)
    72. Jenkins NC, Grossman D (2013). Role of melanin in melanocyte dysregulation of reactive oxygen species. Biomed Res Int, 2013, 908797. (Read full article)
    73. Duffy K, Grossman D (2012). The dysplastic nevus: from historical perspective to management in the modern era: part II. Molecular aspects and clinical management. J Am Acad Dermatol, 67(1), 19.e1-12; quiz 31-2. (Read full article)
    74. Duffy K, Grossman D (2012). The dysplastic nevus: from historical perspective to management in the modern era: part I. Historical, histologic, and clinical aspects. J Am Acad Dermatol, 67(1), 1.e1-16; quiz 17-8. (Read full article)
    75. McKenzie JA, Grossman D (2012). Role of the apoptotic and mitotic regulator survivin in melanoma. Anticancer Res, 32(2), 397-404. (Read full article)
    76. Goodson AG, Florell SR, Boucher KM, Grossman D (2011). A decade of melanomas: identification of factors associated with delayed detection in an academic group practice. Dermatol Surg, 37(11), 1620-30. (Read full article)
    77. Jenkins NC, Liu T, Cassidy P, Leachman SA, Boucher KM, Goodson AG, Samadashwily G, Grossman D (2011). The p16(INK4A) tumor suppressor regulates cellular oxidative stress. Oncogene, 30(3), 265-74. (Read full article)
    78. McKenzie JA, Liu T, Goodson AG, Grossman D (2010). Survivin enhances motility of melanoma cells by supporting Akt activation and {alpha}5 integrin upregulation. Cancer Res, 70(20), 7927-37. (Read full article)
    79. Goodson AG, Florell SR, Hyde M, Bowen GM, Grossman D (2010). Comparative analysis of total body and dermatoscopic photographic monitoring of nevi in similar patient populations at risk for cutaneous melanoma. Dermatol Surg, 36(7), 1087-98. (Read full article)
    80. Goodson AG, Florell SR, Boucher KM, Grossman D (2010). Low rates of clinical recurrence after biopsy of benign to moderately dysplastic melanocytic nevi. J Am Acad Dermatol, 62(4), 591-6. (Read full article)
    81. Goodson AG, Cotter MA, Cassidy P, Wade M, Florell SR, Liu T, Boucher KM, Grossman D (2009). Use of oral N-acetylcysteine for protection of melanocytic nevi against UV-induced oxidative stress: towards a novel paradigm for melanoma chemoprevention. Clin Cancer Res, 15(23), 7434-40. (Read full article)
    82. LaBarbera DV, Modzelewska K, Glazar AI, Gray PD, Kaur M, Liu T, Grossman D, Harper MK, Kuwada SK, Moghal N, Ireland CM (2009). The marine alkaloid naamidine A promotes caspase-dependent apoptosis in tumor cells. Anticancer Drugs, 20(6), 425-36. (Read full article)
    83. Goodson AG, Grossman D (2009). Strategies for early melanoma detection: Approaches to the patient with nevi. J Am Acad Dermatol, 60(5), 719-35; quiz 736-8. (Read full article)
    84. Florell SR, Meyer LJ, Boucher KM, Grossman D, Cannon-Albright LA, Harris RM, Samlowski WE, Zone JJ, Leachman SA (2008). Increased melanocytic nevi and nevus density in a G-34T CDKN2A/p16 melanoma-prone pedigree. J Invest Dermatol, 128(8), 2122-5. (Read full article)
    85. Liu J, Epand R, Durrant D, Grossman D, Epand R, Lee R (2008). Regulation of tBid-induced apoptosis by mitochondrial phospholipid scramblase 3. Biochemistry, 47(4518), 4529.
    86. Florell SR Smoller BR, Boucher KM, Grossman D, Harris RM, Bowen GM, Leachman SA (2008). Sampling of melanocytic nevi for research purposes: A prospective study to determine effect on diagnosis. J Am Acad Dermatol, 59, 814-821.
    87. Liu J, Epand RF, Durrant D, Grossman D, Chi NW, Epand RM, Lee RM (2008). Role of phospholipid scramblase 3 in the regulation of tumor necrosis factor-alpha-induced apoptosis. Biochemistry, 47(15), 4518-29. (Read full article)
    88. Raj D, Liu T, Samadashwily G, Li F, Grossman D (2008). Survivin repression by p53, Rb and E2F2 in normal human melanocytes. Carcinogenesis, 29(1), 194-201. (Read full article)
    89. Cotter MA, Thomas J, Cassidy P, Robinette K, Jenkins N, Florell SR, Leachman S, Samlowski WE, Grossman D (2007). N-acetylcysteine protects melanocytes against oxidative stress/damage and delays onset of ultraviolet-induced melanoma in mice. Clin Cancer Res, 13(19), 5952-8. (Read full article)
    90. Fuller SR, Bowen GM, Tanner B, Florell SR, Grossman D (2007). Digital dermoscopic monitoring of atypical nevi in patients at risk for melanoma. Dermatol Surg, 33(10), 1198-206; discussion 1205-6. (Read full article)
    91. Florell SR, Thomas J, Grossman D (2007). Predominant formation of heavily pigmented dermal melanocytomas resembling 'animal-type' melanomas in hepatocyte growth factor (C57BL/6 x C3H)F1 mice following neonatal UV irradiation. J Cutan Pathol, 34(9), 667-74. (Read full article)
    92. He Y, Liu J, Grossman D, Durrant D, Sweatman T, Lothstein L, Epand RF, Epand RM, Lee RM (2007). Phosphorylation of mitochondrial phospholipid scramblase 3 by protein kinase C-delta induces its activation and facilitates mitochondrial targeting of tBid. J Cell Biochem, 101(5), 1210-21. (Read full article)
    93. Thomas J, Liu T, Cotter MA, Florell SR, Robinette K, Hanks AN, Grossman D (2007). Melanocyte expression of survivin promotes development and metastasis of UV-induced melanoma in HGF-transgenic mice. Cancer Res, 67(11), 5172-8. (Read full article)
    94. Yan H, Thomas J, Liu T, Raj D, London N, Tandeski T, Leachman SA, Lee RM, Grossman D (2006). Induction of melanoma cell apoptosis and inhibition of tumor growth using a cell-permeable Survivin antagonist. Oncogene, 25(52), 6968-74. (Read full article)
    95. Liu T, Biddle D, Hanks AN, Brouha B, Yan H, Lee RM, Leachman SA, Grossman D (2006). Activation of dual apoptotic pathways in human melanocytes and protection by survivin. J Invest Dermatol, 126(10), 2247-56. (Read full article)
    96. Yan H, Brouha B, Liu T, Raj D, Biddle D, Lee R, Grossman D (2006). Proteolytic cleavage of Livin (ML-IAP) in apoptotic melanoma cells potentially mediated by a non-canonical caspase. J Dermatol Sci, 43(3), 189-200. (Read full article)
    97. Raj D, Brash DE, Grossman D (2006). Keratinocyte apoptosis in epidermal development and disease. J Invest Dermatol, 126(2), 243-57. (Read full article)
    98. Florell SR, Meyer LJ, Boucher KM, Hart M, Cannon-Albright LA, Harris RM, Grossman D, Samlowski WE, Zone JJ, Brinton JP, Leachman SA (2005). Nevus distribution in a Utah melanoma kindred with a temperature-sensitive CDKN2A mutation. J Invest Dermatol, 125(6), 1310-2. (Read full article)
    99. Florell SR, Bowen AR, Hanks AN, Murphy KJ, Grossman D (2005). Proliferation, apoptosis, and survivin expression in a spectrum of melanocytic nevi. J Cutan Pathol, 32(1), 45-9. (Read full article)
    100. Zhang W, Hanks AN, Boucher K, Florell SR, Allen SM, Alexander A, Brash DE, Grossman D (2005). UVB-induced apoptosis drives clonal expansion during skin tumor development. Carcinogenesis, 26(1), 249-57. (Read full article)
    101. Bowen AR, Hanks AN, Murphy KJ, Florell SR, Grossman D (2004). Proliferation, apoptosis, and survivin expression in keratinocytic neoplasms and hyperplasias. Am J Dermatopathol, 26(3), 177-81. (Read full article)
    102. Alexander A, Harris RM, Grossman D, Bruggers CS, Leachman SA (2004). Vulvar melanoma: diffuse melanosis and metastasis to the placenta. J Am Acad Dermatol, 50(2), 293-8. (Read full article)
    103. Liu T, Brouha B, Grossman D (2004). Rapid induction of mitochondrial events and caspase-independent apoptosis in Survivin-targeted melanoma cells. Oncogene, 23(1), 39-48. (Read full article)
    104. Karpf AR, Lasek AW, Ririe TO, Hanks AN, Grossman D, Jones DA (2004). Limited gene activation in tumor and normal epithelial cells treated with the DNA methyltransferase inhibitor 5-aza-2'-deoxycytidine. Mol Pharmacol, 65(1), 18-27. (Read full article)
    105. Florell SR, Schmidt SJ, Porter-Gill P, Albertine KH, Murphy KJ, McKinney CB, Boucher KM, Grossman D, Biddle DL, Clayton F, Layfield LJ, Leachman SA (2003). Novel application of a fibrin cell block method to evaluate melanocytic cell populations. Pigment Cell Res, 16(6), 662-9. (Read full article)
    106. Liu J, Dai Q, Chen J, Durrant D, Freeman A, Liu T, Grossman D, Lee RM (2003). Phospholipid scramblase 3 controls mitochondrial structure, function, and apoptotic response. Mol Cancer Res, 1(12), 892-902. (Read full article)
    107. Alexander A, Samlowski WE, Grossman D, Bruggers CS, Harris RM, Zone JJ, Noyes RD, Bowen GM, Leachman SA (2003). Metastatic melanoma in pregnancy: risk of transplacental metastases in the infant. J Clin Oncol, 21(11), 2179-86. (Read full article)
    108. Allen SM, Florell SR, Hanks AN, Alexander A, Diedrich MJ, Altieri DC, Grossman D (2003). Survivin expression in mouse skin prevents papilloma regression and promotes chemical-induced tumor progression. Cancer Res, 63(3), 567-72. (Read full article)
    109. Bowen AR, Hanks AN, Allen SM, Alexander A, Diedrich MJ, Grossman D (2003). Apoptosis regulators and responses in human melanocytic and keratinocytic cells. J Invest Dermatol, 120(1), 48-55. (Read full article)
    110. Diedrich MJ, Warters RL, Grossman D (2002). Amifostine aminothiols and protection of keratinocyte apoptosis and DNA damage. J Invest Dermatol, 119(3), 707-8. (Read full article)
    111. Grossman D, Kim PJ, Blanc-Brude OP, Brash DE, Tognin S, Marchisio PC, Altieri DC (2001). Transgenic expression of survivin in keratinocytes counteracts UVB-induced apoptosis and cooperates with loss of p53. J Clin Invest, 108(7), 991-9. (Read full article)
    112. Grossman D, Kim PJ, Schechner JS, Altieri DC (2001). Inhibition of melanoma tumor growth in vivo by survivin targeting. Proc Natl Acad Sci U S A, 98(2), 635-40. (Read full article)
    113. Grossman D, Altieri DC (2001). Drug resistance in melanoma: mechanisms, apoptosis, and new potential therapeutic targets. Cancer Metastasis Rev, 20(1-2), 3-11. (Read full article)
    114. OConnor DS, Grossman D, Plescia J, Li F, Zhang H, Villa A, Tognin S, Marchisio PC, Altieri DC (2000). Regulation of apoptosis at cell division by p34cdc2 phosphorylation of survivin. Proc Natl Acad Sci U S A, 97(24), 13103-7. (Read full article)
    115. Grossman D, McNiff JM, Li F, Altieri DC (1999). Expression and targeting of the apoptosis inhibitor, survivin, in human melanoma. J Invest Dermatol, 113(6), 1076-81. (Read full article)
    116. Grossman D, McNiff JM, Li F, Altieri DC (1999). Expression of the apoptosis inhibitor, survivin, in nonmelanoma skin cancer and gene targeting in a keratinocyte cell line. Lab Invest, 79(9), 1121-6. (Read full article)
    117. Grossman D, Leffell DJ (1997). The molecular basis of nonmelanoma skin cancer: new understanding. Arch Dermatol, 133(10), 1263-70. (Read full article)
    118. Grossman D, Heald PW, Wang C, Rinder HM (1997). Activated protein C resistance and anticardiolipin antibodies in patients with venous leg ulcers. J Am Acad Dermatol, 37(3 Pt 1), 409-13. (Read full article)
    119. Sarris AH, Esgleyes-Ribot T, Crow M, Broxmeyer HE, Karasavvas N, Pugh W, Grossman D, Deisseroth A, Duvic M (1995). Cytokine loops involving interferon-gamma and IP-10, a cytokine chemotactic for CD4+ lymphocytes: an explanation for the epidermotropism of cutaneous T-cell lymphoma? Blood, 86(2), 651-8. (Read full article)
    120. Grossman D, Lewis DE, Ballas ZK, Duvic M (1994). Idiopathic CD4+ T lymphocytopenia in a patient with mycosis fungoides. J Am Acad Dermatol, 31(2 Pt 1), 275-6. (Read full article)
    121. Grossman D, Rapini RP, Osborne B, Duvic M (1994). Emergence of leprosy in a patient with mycosis fungoides. J Am Acad Dermatol, 30(2 Pt 2), 313-5. (Read full article)
    122. Harris TO, Grossman D, Kappler JW, Marrack P, Rich RR, Betley MJ (1993). Lack of complete correlation between emetic and T-cell-stimulatory activities of staphylococcal enterotoxins. Infect Immun, 61(8), 3175-83. (Read full article)
    123. Mollick JA, Miller GG, Musser JM, Cook RG, Grossman D, Rich RR (1993). A novel superantigen isolated from pathogenic strains of Streptococcus pyogenes with aminoterminal homology to staphylococcal enterotoxins B and C. J Clin Invest, 92(2), 710-9. (Read full article)
    124. Mollick JA, McMasters RL, Grossman D, Rich RR (1993). Localization of a site on bacterial superantigens that determines T cell receptor beta chain specificity. J Exp Med, 177(2), 283-93. (Read full article)
    125. Grossman D, Lamphear JG, Mollick JA, Betley MJ, Rich RR (1992). Dual roles for class II major histocompatibility complex molecules in staphylococcal enterotoxin-induced cytokine production and in vivo toxicity. Infect Immun, 60(12), 5190-6. (Read full article)
    126. Grossman D, Van M, Mollick JA, Highlander SK, Rich RR (1991). Mutation of the disulfide loop in staphylococcal enterotoxin A. Consequences for T cell recognition. J Immunol, 147(10), 3274-81. (Read full article)
    127. Grossman D, Cook RG, Sparrow JT, Mollick JA, Rich RR (1990). Dissociation of the stimulatory activities of staphylococcal enterotoxins for T cells and monocytes. J Exp Med, 172(6), 1831-41. (Read full article)

    Review

    1. Atkins MB, Curiel-Lewandrowski C, Fisher DE, Swetter SM, Tsao H, Aguirre-Ghiso JA, Soengas MS, Weeraratna AT, Flaherty KT, Herlyn M, Sosman JA, Tawbi HA, Pavlick AC, Cassidy PB, Chandra S, Chapman PB, Daud A, Eroglu Z, Ferris LK, Fox BA, Gershenwald JE, Gibney GT, Grossman D, Hanks BA, Hanniford D, Hernando E, Jeter JM, Johnson DB, Khleif SN, Kirkwood JM, Leachman SA, Mays D, Nelson KC, Sondak VK, Sullivan RJ, Merlino G, Melanoma Research Foundation (2021). The State of Melanoma: Emergent Challenges and Opportunities. [Review]. Clin Cancer Res, 27(10), 2678-2697.
    2. March J, Hand M, Truong A, Grossman D (2015). Practical application of new technologies for melanoma diagnosis: Part II. Molecular approaches. [Review]. J Am Acad Dermatol, 72(6), 943-58; quiz 959-60. (Read full article)
    3. Kim CC, Swetter SM, Curiel-Lewandrowski C, Grichnik JM, Grossman D, Halpern AC, Kirkwood JM, Leachman SA, Marghoob AA, Ming ME, Nelson KC, Veledar E, Venna SS, Chen SC (2015). Addressing the knowledge gap in clinical recommendations for management and complete excision of clinically atypical nevi/dysplastic nevi: Pigmented Lesion Subcommittee consensus statement. [Review]. JAMA Dermatol, 151(2), 212-8. (Read full article)
    4. Hand M, Chien A, Grossman D (2015). Screening and non-invasive evaluative devices for melanoma detection: a comparison of commercially available devices and dermoscopic evaluation. [Review]. 2, 005.
    5. Pho L, Grossman D, Leachman SA (2006). Melanoma genetics: a review of genetic factors and clinical phenotypes in familial melanoma. [Review]. Curr Opin Oncol, 18(2), 173-9. (Read full article)
    6. Brash DE, Zhang W, Grossman D, Takeuchi S (2005). Colonization of adjacent stem cell compartments by mutant keratinocytes. [Review]. Semin Cancer Biol, 15(2), 97-102. (Read full article)

    Book Chapter

    1. Cassidy PB, Leachman SA, Grossman D (2012). N-acetylcysteine for Reduction of Oxidative Stress-Damage and Prevention of Melanoma. In RR Watson, S Zibadi (Eds.), Bioactive Dietary Factors and Plant Extracts in Dermatology. New York: Springer.
    2. Grossman D, Leffell DJ (2012). Squamous cell carcinoma. In LA Goldsmith, SI Katz, B Gilchrest, AS Paller, DJ Leffell, K Wolff (Eds.), Fitzpatrick's Dermatology in General Medicine (8th Edition). New York: McGraw-Hill.
    3. Cassidy PB, Grossman D, Leachman SA (2012). Melanoma Prevention. In Emerging Therapeutics for Melanoma (pp. 30-42). Future Medicine Ltd.
    4. Grossman D, Leffell DJ (2008). Squamous cell carcinoma. In K Wolff, LA Goldsmith, SI Katz, B Gilchrest, AS Paller, DJ Leffell (Eds.), Fitzpatrick's Dermatology in General Medicine (7th Edition). New York: McGraw-Hill.
    5. Grossman D, Leffell DJ (2003). Squamous cell carcinoma. In I Freedberg, AZ Eisen, K Wolff, KF Austen, LA Goldsmith, SI Katz (Eds.), Fitzpatrick's Dermatology in General Medicine (6th Edition). New York: McGraw-Hill.
    6. Grossman D, Leffell DJ (1999). The clinical biology and molecular basis of squamous cell carcinoma. In AC Chu, RL Edelson (Eds.), Malignant Tumors of the Skin. New York: Oxford University Press.

    Conference Proceedings

    1. Leachman SA, Smalley KSM, Grossman D, Bowen GM, Messina JL, Berwick M, Glass LF, Swetter SM, Sondak V (2012). Joint melanoma meetings in Tampa enhance communication and collaboration. Expert Rev of Dermatol, 7, 129-131.

    Commentary

    1. Grossman D, Bowen GM (2018). Commentary on impact of National Comprehensive Cancer Network Guidelines on Case Selection and Outcomes for Sentinel Lymph Node Biopsy in Thin Melanoma. Dermatol Surg, (44), 502-503.
    2. Kim CC, Swetter S, Curiel-Lewandrowski, Grichnik J, Grossman D, Halpern AC, Kirkwood JM, Leachman SA, Marghoob AA, Ming ME, Nelson KC, Veledar E, Venna SS, Chen S (2015). Complete excision of atypical/dysplastic nevi: Addressing the gap in clinical practice recommendations and need for more data to guide management. Pigmented Lesion Subcommittee consensus statement. JAMA Dermatol, 151(2), 212-218.
    3. Grossman D (2011). Failure to compare dermoscopy findings of pigmented lesions on your patient: Comment on "Dermoscopy of patients with multiple nevi". Arch Dermatol, 147(1), 50. (Read full article)
    4. Cotter MA, Florell SR, Leachman SA, Grossman D (2008). Reply to responses to "Absence of senescence-associated beta-galactosidase activity in human melanocytic nevi in vivo". J Invest Dermatol, 128, 1583-1584.
    5. Grossman D (2004). Imatinib mesylate for melanoma: will a new target be revealed? J Invest Dermatol, 123(6), xi-xiii. (Read full article)
    6. Grossman D, Duvic M (1995). Reply to response to "Idiopathic CD4 T-lymphocytopenia in a patient with mycosis fungoides". J Am Acad Dermatol, 32, 1064.

    Case Report

    1. Shah A, Hyngstrom J, Florell SR, Grossman D (2019). Use of the Pigmented Lesion Assay to rapidly screen a patient with numerous clinically atypical pigmented lesions. JAAD Case Rep, 5(12), 1048-1050. (Read full article)

    Editorial

    1. Varedi A, Wu YP, Klein SZ, Leachman SA, Grossman D (2018). Mineral sunscreens not recommended by Consumer Reports: Suggestions to improve the review process. J Am Acad Dermatol, 80(3), 832-833. (Read full article)

    Letter

    1. Chang MS, Leachman SA, Berry EG, Curiel-Lewandrowski C, Geller AC, Grossman D, Kim CC, Stein JA, Swetter SM, Hartman RI (2021). Changes in melanoma care practices during the COVID-19 pandemic: a multi-institutional cross-sectional survey. [Letter to the editor]. Dermatol Online J, 27(4). (Read full article)
    2. Grossman D, Sweeney C, Doherty JA (2021). The Rapid Rise in Cutaneous Melanoma Diagnoses. [Letter to the editor]. N Engl J Med, 384(14), e54. (Read full article)
    3. Grossman D, Florell SR, Duffy KL, Bowen GM (2019). Histologic criteria for assessing surgical margins in melanoma in situ. [Letter to the editor]. J Am Acad Dermatol, 82(4), e133-e134. (Read full article)
    4. Varedi A, Gardner LJ, Kim CC, Chu EY, Ming ME, Leachman SA, Curiel-Lewandrowski C, Swetter SM, Grossman D (2019). Use of new molecular tests for melanoma by pigmented-lesion experts. [Letter to the editor]. J Am Acad Dermatol, 82(1), 245-247. (Read full article)
    5. Varedi A, Bishop MD, Boucher KM, Kim CC, Grossman D (2019). Powering a prospective melanoma chemoprevention trial in high-risk cohorts. [Letter to the editor]. Int J Dermatol, 58(11), e232-e234. (Read full article)
    6. Duffy KL, Truong A, Bowen GM, Andtbacka RH, Hyngstrom J, Bowles T, Grossmann K, Khong H, Hyde M, Florell SR, Bowen AR, Wada D, Grossman D (2014). Adequacy of 5-mm surgical excision margins for non-lentiginous melanoma in situ. [Letter to the editor]. J Am Acad Dermatol, 71(4), 835-8. (Read full article)
    7. Grossman D, Duffy KL, Bowen GM (2012). Surgical margins for melanoma in situ. [Letter to the editor]. J Am Acad Dermatol, 67(5), 1068-9; author reply 1069-71. (Read full article)
    8. Cotter MA, Florell SR, Leachman SA, Grossman D (2007). Absence of senescence-associated beta-galactosidase activity in human melanocytic nevi in vivo. [Letter to the editor]. J Invest Dermatol, 127(10), 2469-71. (Read full article)
    9. McGovern TW, Grossman D, Fitzgerald D, Glusac EJ, Leffell D (1999). Status of residual tumor in patients with squamous cell carcinoma referred for Mohs micrographic surgery. [Letter to the editor]. Arch Dermatol, 135(12), 1557-9. (Read full article)
    10. Swana HS, Grossman D, Anthony JN, Weiss RM, Altieri DC (1999). Tumor content of the antiapoptosis molecule survivin and recurrence of bladder cancer. [Letter to the editor]. N Engl J Med, 341(6), 452-3. (Read full article)
    11. Duvic M, Grossman D (1994). More on acyclovir for chickenpox. [Letter to the editor]. N Engl J Med, 331(1), 59. (Read full article)
    12. Grossman D, Duvic M (1993). Cutaneous T-cell lymphoma after blood transfusion. [Letter to the editor]. Lancet, 342(8885), 1483. (Read full article)

    Other

    1. Himbert C, Hathaway CA, Daniels B, Salas K, Ashworth A, Gigic B, Lin T, Viskochil R, Kirchhoff AC, Grossman D, Ose J, Tward J, Scaife C, Figueiredo JC, Toriola AT, Beck A, Shibata D, Gonzalez BD, Matsen C, Christenson C, Ma DS, Colman H, Hunt JP, Jones KB, Lee CJ, Larson M, Onega T, Akerley WL, Li CI, Schneider M, Penedo FJ, Siegel EM, Tworoger SS, Ulrich CM, Peoples AR (2021). Impact of the COVID-19 pandemic on exercise habits among cancer patients. United States. (Read full article)

    Patent

    1. Grossman D (2008). Use of N-acetylcysteine for inhibition of UV-induced skin cancer. U.S. Patent No. Ref. No. 083404-0153, international PCT US08/62893; U.S. Provisional Patent No. 60/916703. Washington, D.C.:U.S. Patent and Trademark Office.
    2. Grossman D (2007). Use of N-acetylcystein for chemoprevention of UV-induced melanoma, University of Utah Technology Commercialization Office.
    3. Grossman D, Yan H (2006). A cell-permeable (TAT) Survivin antagonist to treat melanoma.

  • News & Podcasts

    News

    Podcasts